CTLA-4Ig: uses and future directions.
Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is a member of the CD28 receptor family. Blocking CD28 interaction with its ligands through the use of CTLA-4Ig might contribute to better control of dysregulated immune response processes. The ligands binding to CTLA-4 are the B7 family members, B7-1 (CD80) and B7-2 (CD86). CTLA-4Ig is now a Food and Drug Administration-approved drug for use treating patients with Rheumatoid arthritis (RA) but its use is explored also in other autoimmune diseases, transplantation as well as allergic diseases. Patents related to CTLA-4 function as well as possible clinical applications are discussed in this paper.
Ben-Shoshan
Moshe
M
Department of Pediatric Allergy and Immunology, McGill University Health Center, Montreal, QC, Canada. daliamoshebs@gmail.com
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD / Q000276:immunology*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy; D018122:B7-1 Antigen / Q000276:immunology / Q000378:metabolism; D051940:B7-2 Antigen / Q000276:immunology / Q000378:metabolism; D018106:CD28 Antigens / Q000276:immunology / Q000378:metabolism; D060908:CTLA-4 Antigen; D002986:Clinical Trials as Topic; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism
D015703:Antigens, CD; D018501:Antirheumatic Agents; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000069594:Abatacept